All Blogs / Health / Diseases & Conditions / Multiple Sclerosis / New

Poetic Justice to be a Party Pooper

In my angst-ridden teen years, I wrote poetry. It was truly dreadful and should have disappeared in the wash of personal history. Luckily, it was the mid-’70s, and in those pre-internet days, it was committed only in pen to scrappy paper rather than as a confessional to the world. Show More Summary

What I Learned About My MS While on Vacation

You wouldn’t think that a guy who was diagnosed with MS more than 37 years ago would still be able to learn a thing or two about his disease. But that’s exactly what I did while on vacation about a week ago. I guess I really did know these things, but it took a trip […] The post What I Learned About My MS While on Vacation appeared first on Multiple Sclerosis News Today.

Toyota Foundation and Nesta Launch $4 Million Global Challenge to Create ‘Smart’ Mobility Devices

Teams of inventors working to improve mobility for people with lower-limb paralysis, including those with multiple sclerosis (MS), are invited to take part in a $4 million technology challenge launched by Toyota Mobility Foundation and Nesta’s Challenge Prize Centre. Show More Summary

Novartis’ Gilenya Improves Cognition, Reduces Relapses and MS Lesions, Phase 4 Trial Shows

Novartis‘ Gilenya and interferon beta-1b-based therapies stop multiple sclerosis patients’ cognitive decline, a Phase 4 clinical trial shows. Gilenya (fingolimod) also reduces patients’ relapses and the number of their brain lesions — areas where a protein coating that protects nerve cells has deteriorated, researchers found. Show More Summary

Finding Peace During the Holidays

The Christmas season is upon us — decorations, shopping, and get-togethers dominate the month of December. If you tune into the Hallmark channel you will see this season as synonymous with love, laughter, and an abundance of cheer. With joy the prevailing theme it can be difficult to experience and admit feeling anything but. Show More Summary

Silence: A Missed Opportunity for Education?

My mouth is dry. My heart is pounding. I'm beginning to sweat. No, I'm not about to perform on a stage or give a speech to a roomful of people... and yet... everyone is looking at me—not at him—waiting, expecting me to do something....

Advances in MRI Readings

My neurologist orders an annual MRI to see if any major changes have occurred, and last year my imaging included NeuroQuant software. NeuroQuant is still relatively unknown in the multiple sclerosis patient community. It is a measuring...Show More Summary

Partners in Huge Cannabis Therapy Operation Planned for Australia Apply for Licenses

Two companies that plan a huge cannabis-growing and research facility in Australia have applied for licenses to run the operations, whose products could benefit multiple sclerosis patients. MYM Nutraceuticals and PUF Ventures Australia asked the Australian Office of Drug Control for both medical cannabis and cannabis research licenses. Show More Summary

University of Illinois Researchers Win $300,000 Falk Award to Improve MS Drug Delivery

A research team at the University of Illinois College of Medicine (UIC) has received $300,000 from the Falk Medical Research Trust to develop a novel drug delivery method that could improve the treatment of patients with multiple sclerosis (MS). Show More Summary

6 Tips to Enjoy This Merry Month of December

Whenever I turn the pages of my wall calendar to December, I look at the word itself ? DECEMBER ? and my heart fills with joy. And admittedly a little dread. Joy, because my husband and son have birthdays a week apart, it’s holiday time,...Show More Summary

National MS Society Endorses US-Canada Registry Aiming to Advance Research and Patient Care

The National Multiple Sclerosis Society has endorsed the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS), a collaborative effort involving other multiple sclerosis (MS) registries, clinicians, researchers and patients in the U.S. Show More Summary

Health Canada Approves Merck’s Mavenclad to Treat RRMS

Canadians with relapsing-remitting multiple sclerosis (RRMS) can now receive Merck’s Mavenclad (cladribine tablets), now that Health Canada has approved Mavenclad as a therapy to reduce the frequency of MS exacerbations and delay disease progression. Show More Summary

5 Tips for Going to Shows and Events With MS Disabilities

Going to a show to see a band or a play or a big event may be your idea of having fun, and MS-related challenges — especially mobility — don’t have to be game-changers and keep you from the spectacle of it all, especially with a little planning. Show More Summary

Treat Others as You Wish to Be Treated: An Open Letter to Our Spouses and Partners

My journey in life has allowed me to connect with and meet people from all over the world. For this, I am blessed. I’ve met many diagnosed with MS and other chronic illnesses. All of our experiences are different and we have varying levels of support. Show More Summary

Human Vaccines Project Studies Aim to Unveil Workings of Immune System

Scientists announced positive and encouraging outcomes from two clinical studies — running as part of the larger Human Vaccines Project — aiming to unravel the mechanisms that underlie our immune system’s ability to fight disease. The...Show More Summary

Patient Stories: What It’s Like Being an Athlete With MS

“You have multiple sclerosis” is something that no one wants to hear. Some people hear it but have no idea what it means. Some think they’ll end up in a wheelchair and that their life will never be the same. MORE: How yoga and aquatic exercise can ease some MS-related symptoms That’s somewhat true. Show More Summary

Social Media’s World of MS Misinformation

I’m worried about social media. Specifically, I’m worried about the many MS-related groups in the Facebook world. There are general MS groups and there are groups dedicated to specific MS treatments. I belong to several, and though there’s...Show More Summary

Laquinimod Fails to Slow Brain Atrophy and PPMS Progression, Says Developer Active Biotech

Sweden's Active Biotech said its experimental therapy Laquinimod failed to meet the primary and secondary objectives of Phase 2 clinical trial evaluating the drug's potential to treat primary progressive multiple sclerosis. Laquinimod,...Show More Summary

Copyright © 2015 Regator, LLC